Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 2Virus Diseases 1Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1Adenoviridae Infections 1

Interventions

Oxaliplatin 15Fluorouracil 13Bevacizumab 13Leucovorin 10Capecitabine 8Folfox protocol 7Irinotecan 6IFL protocol 4Cetuximab 4Folic Acid 3Aspirin 3atezolizumab 2XELOX 2Surgical Procedures, Operative 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Chemotherapy, Adjuvant 2trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1sulindac sulfone 1spartalizumab 1sacituzumab govitecan 1regorafenib 1raltitrexed 1pertuzumab 1irinotecan sucrosofate 1folfirinox 1envafolimab 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Colorectal Neoplasms × Mitomycin × Clear all
NCT00294359 2007-08-22

The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Australasian Gastro-Intestinal Trials Group

Phase 2/3 Completed
333 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡